Why Summit Therapeutics Stock Was a Winner Today
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
JMP Securities Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $32
JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40